At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 64 enrolled
Drug / intervention
motexafin gadolinium +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Motexafin-Gadolinium (NSC 695238, IND #55583) and Involved Field Radiation Therapy for Intrinsic Pontine Glioma of Childhood
In Brief
A Phase 2 clinical trial evaluating motexafin gadolinium and 3-dimensional conformal radiation therapy for Untreated Childhood Brain Stem Glioma. Completed, enrolled 64 participants across 1 site.
Detailed Summary
This phase II trial is studying how well giving motexafin gadolinium together with radiation therapy works in treating young patients with pontine glioma. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs, such as motexafin gadolinium, may make tumor cells more sensitive to radiation therapy. Giving motexafin gadolinium together with radiation therapy may kill more tumor cells.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUntreated Childhood Brain Stem Glioma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 2006
Enrollment StartJun 2007
Primary CompletionApr 2010
TodayJul 2026
First PostedOct 13, 2006
Enrollment StartJun 1, 2007
Primary CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 19.7 years ago
Interventions
motexafin gadoliniumdrug
Given IV
3-dimensional conformal radiation therapyradiation
Undergo focal cranial radiotherapy